NCT01578772

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

Telmisartan and Flow-Mediated Dilatation in Older HIV-Infected Patients at Risk for Cardiovascular Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: University of California, Los Angeles · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This research study is to see whether blood vessel function, an early sign of heart disease, improves in HIV-infected men and women who take telmisartan for 12 weeks. The investigators will be looking at how a blood vessel in the arm, called the brachial artery, changes in response to stress before and after taking telmisartan. To determine how well the blood vessel functions, the investigators will be using an ultrasound machine. Telmisartan is not an HIV medication. It is an FDA-approved medication designed to treat blood pressure, but has been shown to improve blood vessel function in HIV-negative people with and without high blood pressure. Telmisartan is made by Boehringer Ingelheim, and this trial is sponsored by The Campbell Foundation.

Conditions

• Endothelial Dysfunction

Interventions

Type	Name	Description
DRUG	Telmisartan	80mg tablets po daily for 6 weeks

Timeline

• Start date: 2012-08-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2012-04-17
• Last updated: 2014-12-08
• Results posted: 2014-12-08

Locations

1 site across 1 country: United States